Track topics on Twitter Track topics that are important to you
The US Food and Drug Administration and European Medicines Agency have granted approval to TAS-102 for the treatment of refractory metastatic colorectal cancer.1,2 In The Lancet Oncology, Yasutoshi Kuboki and colleagues report on the results of C-TASK FORCE,3 a phase 1/2 study on the combination of TAS-102 with bevacizumab. The rationale for this study was sound and strong. Phosphorylated trifluridine concentration and tumour growth inhibition are increased with the combination of TAS-102 and bevacizumab compared with either drug alone.
Original Article: [Comment] New perspectives for TAS-102: TASK successful?NEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...